MELanoma Brain Metastasis Treated With CYberknife

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorEuropean Institute of Oncology

About this trial

Melanoma is a type of cancer that can spread to the brain, making the disease harder to treat and worsening both survival and quality of life.

In recent years, treatments have improved significantly thanks to advances in surgery, radiotherapy, immunotherapy, and targeted therapy. These new treatments have greatly increased survival rates for patients with metastatic melanoma.

This study focuses on stereotactic radiosurgery, a highly precise form of radiotherapy used to treat brain metastases. Researchers want to better understand how this treatment works when combined with immunotherapy or targeted therapy, and whether the timing and sequence of treatments can improve outcomes.

Between 2026 and 2028, patients treated at the IEO for melanoma brain metastases will be observed and their clinical data collected. The goal is to improve future treatment strategies and help doctors choose the best therapeutic approach for each patient.

Eligibility criteria

Qualifiers

Age > 18

Written informed consent for treatment and research purposes

Melanoma Brain Metastases (MBM) diagnosed with brain MRI/CT

MBM treatable with stereotactic radiotherapy

Disqualifiers

Leptomeningeal neoplastic infiltration

Previous whole-brain radiotherapy or surgical removal of brain metastases

Patients with histological diagnosis of non-cutaneous melanoma (e.g. uveal melanoma)

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

50 Participants
are grouped into 1 trial group

Sponsors and collaborators

European Institute of Oncology

Lead sponsor

Accuray Incorporated

Collaborator